Investing.com - Ascendis Pharma AS reported on Wednesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Ascendis Pharma AS announced earnings per share of €7 on revenue of €7.77M. Analysts polled by Investing.com anticipated EPS of €-2.29 on revenue of €3.17M.
Ascendis Pharma AS shares are down 20.85% from the beginning of the year and are trading at €100.00 , down-from-52-week-high.They are under-performing the Nasdaq which is down 12.1% from the start of the year.
Ascendis Pharma AS shares lost 6.09% in after-hours trade the report.
Ascendis Pharma AS follows other major Healthcare sector earnings this month
Ascendis Pharma AS's report follows an earnings matched by Roche Holding ADR on February 3, who reported EPS of €1.29 on revenue of €17.54B, compared to forecasts EPS of €1.29 on revenue of €17.1B.
Pfizer had beat expectations on February 8 with fourth quarter EPS of €1.08 on revenue of €23.84B, compared to forecast for EPS of €0.8742 on revenue of €24.16B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar